Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL

Clinical trial NCT02747732 · UNKNOWN

Trial details

NCT number: NCT02747732
Sponsor: Meirav Kedmi MD
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Diffuse Large B Cell Lymphoma Primary Mediastinal (Thymic) Large B-cell Lymphoma Transformed Indolent Lymphoma Recurrent Disease Refractory Cancer

Start date: 2016-12-01
Primary completion: 2020-06-01
Enrollment: 72

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.